News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Nutri Pharmaceuticals Research, Inc. Collaborates with Baylor University



9/19/2007 12:00:20 PM

LAS VEGAS--(BUSINESS WIRE)--Nutri Pharmaceuticals Research, Inc. (Pink Sheets: NRPR) announced today that it has been selected to collaborate on the development of a dry formulation for Triheptanoin by Dr. Charles Roe, Medical Director of the Institute of Metabolic Disease at Baylor University Medical Center, Dallas. Triheptanoin is a unique medium-odd chain triglyceride that has provided significant benefit to many patients with inherited biochemical disorders. Clinical features of these disorders can include muscle weakness, pain and breakdown of muscle tissue (rhabdomyolysis), and cardiomyopathy (disease of the heart muscle) all resulting from the lack of proper energy production within the cells.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES